A VACCINE against SRS (salmon rickettsial septicaemia) has received marketing authorisation from the Chilean authorities, reported Pharmaq.
The approval to sell the company’s Alpha Ject LiVac® SRS vaccine is a major technology milestone for the fish farming industry, said Pharmaq.
Years of research, development and documentation ensure a high level of protection as well as being safe for the fish and the environment.
‘Our innovative drive is based on the aquaculture industry’s need to produce safe and healthy seafood,’ said Pharmaq president Morten Kr Nordstad.
‘We are confident that this ground breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable and reliable fish production.’
SRS is considered to be the most important disease problem in the Chilean salmon farming industry. The disease is caused by the bacterium Piscirickettsia salmonis and has caused major economic losses in the aquaculture industry since its appearance in 1989.
The disease affects all three species farmed in Chile: Atlantic salmon, rainbow trout and coho salmon.